{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T04:08:35Z","timestamp":1728965315124},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"DOI":"10.7759\/cureus.71428","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:17:24Z","timestamp":1728908244000},"source":"Crossref","is-referenced-by-count":0,"title":["Navigating Therapeutic Challenges of Pyoderma Gangrenosum in Felty's Syndrome: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Victor D","family":"Acu\u00f1a-Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Sanchez Sol\u00eds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose A","family":"Ram\u00edrez-V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Fischer Rouyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iv\u00e1n de Jes\u00fas","family":"Hern\u00e1ndez Galarza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.130","article-title":"Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study","volume":"132","author":"Langan SM","year":"2012","unstructured":"Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012, 132:2166-70. 10.1038\/jid.2012.130","journal-title":"J Invest Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-018-0356-7","article-title":"Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis","volume":"19","author":"Kridin K","year":"2018","unstructured":"Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018, 19:479-87. 10.1007\/s40257-018-0356-7","journal-title":"Am J Clin Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2023.12.002","article-title":"Treatment of pyoderma gangrenosum","volume":"42","author":"Tan MG","year":"2024","unstructured":"Tan MG, Tolkachjov SN. Treatment of pyoderma gangrenosum. Dermatol Clin. 2024, 42:183-92. 10.1016\/j.det.2023.12.002","journal-title":"Dermatol Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0014-2565(02)71143-0","article-title":"Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyltransferase (TPMT) activity (Article in Spanish)","volume":"202","author":"Gisbert JP","year":"2002","unstructured":"Gisbert JP, Gomoll\u00f3n F, Mat\u00e9 J, Pajares JM. Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyltransferase (TPMT) activity (Article in Spanish). Rev Clin Esp. 2002, 202:555-62. 10.1016\/s0014-2565(02)71143-0","journal-title":"Rev Clin Esp"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7326\/M21-4675","article-title":"Race, genotype, and azathioprine discontinuation: a cohort study","volume":"175","author":"Dickson AL","year":"2022","unstructured":"Dickson AL, Daniel LL, Jackson E, et al.. Race, genotype, and azathioprine discontinuation: a cohort study. Ann Intern Med. 2022, 175:1092-9. 10.7326\/M21-4675","journal-title":"Ann Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01931-3","article-title":"Pyoderma gangrenosum: treatment options","volume":"83","author":"Dissemond J","year":"2023","unstructured":"Dissemond J, Marzano AV, Hampton PJ, Ortega-Loayza AG. Pyoderma gangrenosum: treatment options. Drugs. 2023, 83:1255-67. 10.1007\/s40265-023-01931-3","journal-title":"Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese CA","year":"2022","unstructured":"Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzano AV. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022, 23:615-34. 10.1007\/s40257-022-00699-8","journal-title":"Am J Clin Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e31802eb078","article-title":"Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy","volume":"26","author":"Teasley LA","year":"2007","unstructured":"Teasley LA, Foster CS, Baltatzis S. Sclerokeratitis and facial skin lesions: a case report of pyoderma gangrenosum and its response to dapsone therapy. Cornea. 2007, 26:215-9. 10.1097\/ICO.0b013e31802eb078","journal-title":"Cornea"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418782140","article-title":"Evaluating the efficacy of topical dapsone treatment for pyoderma gangrenosum: a retrospective case series","volume":"22","author":"Li DG","year":"2018","unstructured":"Li DG, Din RS, Tsiaras WG, Mostaghimi A. Evaluating the efficacy of topical dapsone treatment for pyoderma gangrenosum: a retrospective case series. J Cutan Med Surg. 2018, 22:650-1. 10.1177\/1203475418782140","journal-title":"J Cutan Med Surg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2019.1600670","article-title":"Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone","volume":"15","author":"Molinelli E","year":"2019","unstructured":"Molinelli E, Paolinelli M, Campanati A, Brisigotti V, Offidani A. Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone. Expert Opin Drug Metab Toxicol. 2019, 15:367-79. 10.1080\/17425255.2019.1600670","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1848562","article-title":"Pyoderma gangrenosum as a presenting feature of undifferentiated spondyloarthropathy with erosive inflammatory arthritis","volume":"2020","author":"Kaler J","year":"2020","unstructured":"Kaler J, Sheffield S, Thway M, Ramsubeik K, Kaeley G. Pyoderma gangrenosum as a presenting feature of undifferentiated spondyloarthropathy with erosive inflammatory arthritis. Case Rep Rheumatol. 2020, 2020:1848562. 10.1155\/2020\/1848562","journal-title":"Case Rep Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxac023","article-title":"Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: a case report and review of the literature","volume":"7","author":"Ohmura SI","year":"2023","unstructured":"Ohmura SI, Homma Y, Hanai S, Otsuki Y, Miyamoto T. Successful switching treatment of adalimumab for refractory pyoderma gangrenosum in a patient with rheumatoid arthritis with prior use of tumour necrosis factor inhibitors: a case report and review of the literature. Mod Rheumatol Case Rep. 2023, 7:9-13. 10.1093\/mrcr\/rxac023","journal-title":"Mod Rheumatol Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/302182-navigating-therapeutic-challenges-of-pyoderma-gangrenosum-in-feltys-syndrome-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:17:25Z","timestamp":1728908245000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/302182-navigating-therapeutic-challenges-of-pyoderma-gangrenosum-in-feltys-syndrome-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.71428","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}